SeaStar Medical will announce its Q1 financial results on May 13, 2026, with a subsequent webcast and conference call.
Quiver AI Summary
SeaStar Medical Holding Corporation announced that it will report its first quarter financial results on May 13, 2026, after market close and will host a webcast and conference call at 4:30 p.m. ET to discuss these results and the company's business progress. SeaStar Medical, focused on transforming treatments for critically ill patients facing organ failure, received FDA approval for its product QUELIMMUNE in 2024, marking it as the only approved treatment for life-threatening Acute Kidney Injury in critically ill pediatric patients. The company is advancing its Selective Cytopheretic Device (SCD) therapy, which has received Breakthrough Device Designation by the FDA for several indications. Currently, SeaStar is conducting a pivotal clinical trial for its SCD therapy in adult patients with Acute Kidney Injury.
Potential Positives
- SeaStar Medical is set to report its first quarter financial results, signaling transparency and communication with investors regarding its business performance.
- The company's first commercial product, QUELIMMUNE, is the only FDA-approved treatment for life-threatening Acute Kidney Injury in critically ill pediatric patients, highlighting its unique position in the market.
- SeaStar Medical's Selective Cytopheretic Device therapy has received Breakthrough Device Designation from the FDA for six therapeutic indications, potentially accelerating its approval process and improving market competitiveness.
- The ongoing NEUTRALIZE-AKI pivotal clinical trial demonstrates the company's commitment to addressing a major unmet need in adult patients with Acute Kidney Injury, which could lead to significant growth opportunities and market impact.
Potential Negatives
- There is a lack of detailed information about the company’s financial health ahead of the earnings report, which may raise concerns among investors regarding its performance and future outlook.
- The necessity for preregistration to attend the conference call may limit investor participation and access to important information about the company's performance.
- The sole focus on its first commercial product, QUELIMMUNE, raises concerns about the company's diversification and reliance on a single product for revenue in a highly competitive healthcare market.
FAQ
When will SeaStar Medical report its first quarter financial results?
SeaStar Medical will report its first quarter financial results on May 13, 2026, after market close.
How can I access the SeaStar Medical webcast?
The live webcast and replay of the financial results can be found on SeaStar Medical's official website.
What is QUELIMMUNE and its significance?
QUELIMMUNE is SeaStar Medical's FDA-approved product for treating life-threatening Acute Kidney Injury in critically ill pediatric patients.
What is the NEUTRALIZE-AKI clinical trial?
The NEUTRALIZE-AKI trial tests SeaStar Medical's Selective Cytopheretic Device therapy for adult patients with Acute Kidney Injury.
How can I contact SeaStar Medical Investor Relations?
You can contact SeaStar Medical Investor Relations at [email protected] for inquiries.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$ICU Insider Trading Activity
$ICU insiders have traded $ICU stock on the open market 2 times in the past 6 months. Of those trades, 2 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $ICU stock by insiders over the last 6 months:
- MICHAEL MESSINGER (Chief Financial Officer) purchased 14,500 shares for an estimated $5,098
- JENNIFER A BAIRD purchased 4,200 shares for an estimated $987
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API.
$ICU Hedge Fund Activity
We have seen 3 institutional investors add shares of $ICU stock to their portfolio, and 24 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- VANGUARD GROUP INC removed 339,640 shares (-90.0%) from their portfolio in Q4 2025, for an estimated $81,513
- GEODE CAPITAL MANAGEMENT, LLC removed 258,922 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $62,141
- XTX TOPCO LTD removed 48,558 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $11,653
- TORONTO DOMINION BANK removed 22,500 shares (-90.0%) from their portfolio in Q4 2025, for an estimated $5,400
- MILLENNIUM MANAGEMENT LLC removed 17,967 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $43,120
- TYCHE WEALTH PARTNERS LLC removed 15,930 shares (-90.0%) from their portfolio in Q4 2025, for an estimated $3,823
- PNC FINANCIAL SERVICES GROUP, INC. removed 15,727 shares (-90.0%) from their portfolio in Q4 2025, for an estimated $3,774
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.
Full Release
DENVER, May 06, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that it will report its first quarter financial results after market close on Wednesday, May 13, 2026, and host a webcast and conference call to discuss its financial results and business progress.
| Date/Time: | Wednesday, May 13, 2026, at 4:30 p.m. ET / 2:30 p.m. MT |
| Webcast: | The live webcast and replay can be found here . |
| Register for the call: | Preregistration is required to attend the live call and can be accessed here . A pin code and dial in number will be provided with registration. |
A replay of the call will be available after 7:30 p.m. ET and can be accessed here .
About SeaStar Medical
SeaStar Medical is a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life. SeaStar Medical’s first commercial product, QUELIMMUNE (SCD-PED) , was approved in 2024 by the U.S. Food and Drug Administration (FDA). It is the only FDA approved product for the ultra-rare condition of life-threatening Acute Kidney Injury (AKI) due to sepsis or a septic condition requiring renal replacement therapy (RRT) in critically ill pediatric patients. SeaStar Medical’s Selective Cytopheretic Device (SCD) therapy has been awarded Breakthrough Device Designation for six therapeutic indications by the FDA, enabling the potential for a speedier pathway to approval and preferable reimbursement dynamics at commercial launch. The company is currently conducting the NEUTRALIZE-AKI pivotal clinical trial of its SCD therapy in adult patients with AKI requiring continuous renal replacement therapy, a life-threatening condition with no effective treatment options that impacts over 200,000 adults in the U.S. annually.
For more information visit www.seastarmedical.com or visit us on LinkedIn or X .
Contact:
SeaStar Investor Relations:
[email protected]
